201 related articles for article (PubMed ID: 2142233)
1. Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat.
di Salle E; Zaccheo T; Ornati G
J Steroid Biochem; 1990 Jun; 36(3):203-6. PubMed ID: 2142233
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacological effects of toremifene metabolites.
Kangas L
Cancer Chemother Pharmacol; 1990; 27(1):8-12. PubMed ID: 2147128
[TBL] [Abstract][Full Text] [Related]
3. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats.
Qu Q; Zheng H; Dahllund J; Laine A; Cockcroft N; Peng Z; Koskinen M; Hemminki K; Kangas L; Väänänen K; Härkönen P
Endocrinology; 2000 Feb; 141(2):809-20. PubMed ID: 10650964
[TBL] [Abstract][Full Text] [Related]
4. Review of the pharmacological properties of toremifene.
Kangas L
J Steroid Biochem; 1990 Jun; 36(3):191-5. PubMed ID: 2142231
[TBL] [Abstract][Full Text] [Related]
5. Antitumor effects of combination toremifene and medroxyprogesterone acetate (MPA) in vitro and in vivo.
Kangas L; Grönroos M
J Steroid Biochem; 1990 Jun; 36(3):253-7. PubMed ID: 2142248
[TBL] [Abstract][Full Text] [Related]
6. Antitumor actions of toremifene in the 7,12-dimethylbenzanthracene (DMBA)-induced rat mammary tumor model.
Robinson SP; Mauel DA; Jordan VC
Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1817-21. PubMed ID: 2975594
[TBL] [Abstract][Full Text] [Related]
7. Antitumor effects of droloxifene, a new antiestrogen drug, against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in rats.
Kawamura I; Mizota T; Kondo N; Shimomura K; Kohsaka M
Jpn J Pharmacol; 1991 Oct; 57(2):215-24. PubMed ID: 1812300
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen.
Löser R; Seibel K; Roos W; Eppenberger U
Eur J Cancer Clin Oncol; 1985 Aug; 21(8):985-90. PubMed ID: 4043181
[TBL] [Abstract][Full Text] [Related]
9. A new triphenylethylene compound, Fc-1157a. II. Antitumor effects.
Kangas L; Nieminen AL; Blanco G; Grönroos M; Kallio S; Karjalainen A; Perilä M; Södervall M; Toivola R
Cancer Chemother Pharmacol; 1986; 17(2):109-13. PubMed ID: 2941177
[TBL] [Abstract][Full Text] [Related]
10. Biological activities of tamoxifen aziridine, an antiestrogen-based affinity label for the estrogen receptor, in vivo and in vitro.
Wei LL; Mangel WF; Katzenellenbogen BS
J Steroid Biochem; 1985 Dec; 23(6A):875-81. PubMed ID: 3937947
[TBL] [Abstract][Full Text] [Related]
11. Time-related effects of a triphenylethylene antiestrogen on estrogen-induced changes in uterine weight, estrogen receptors, and endometrial sensitivity in rats.
Trivedi RN; Chauhan SC; Dwivedi A; Kamboj VP; Singh MM
Contraception; 1995 Jun; 51(6):367-79. PubMed ID: 7554978
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and scintigraphy of 11C-toremifene in rats bearing DMBA-induced mammary carcinoma.
Kangas L; Haaparanta M; Paul R; Roeda D; Sipilä H
Pharmacol Toxicol; 1989 Apr; 64(4):373-7. PubMed ID: 2526330
[TBL] [Abstract][Full Text] [Related]
13. Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse.
Robinson SP; Jordan VC
Cancer Res; 1989 Apr; 49(7):1758-62. PubMed ID: 2522347
[TBL] [Abstract][Full Text] [Related]
14. Comparative pharmacodynamic analysis of TAT-59 and tamoxifen in rats bearing DMBA-induced mammary carcinoma.
Toko T; Shibata J; Sugimoto Y; Yamaya H; Yoshida M; Ogawa K; Matsushima E
Cancer Chemother Pharmacol; 1995; 37(1-2):7-13. PubMed ID: 7497599
[TBL] [Abstract][Full Text] [Related]
15. Expression of the c-Ha-ras and neu oncogenes in DMBA-induced, anti-estrogen-treated rat mammary tumors.
Vuorio T; Wärri A; Sandberg M; Alitalo K; Vuorio E
Int J Cancer; 1988 Nov; 42(5):774-9. PubMed ID: 2972630
[TBL] [Abstract][Full Text] [Related]
16. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect.
Yamamoto Y; Shibata J; Yonekura K; Sato K; Hashimoto A; Aoyagi Y; Wierzba K; Yano S; Asao T; Buzdar AU; Terada T
Clin Cancer Res; 2005 Jan; 11(1):315-22. PubMed ID: 15671561
[TBL] [Abstract][Full Text] [Related]
17. Introduction to toremifene.
Kangas L
Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S3-7. PubMed ID: 2149282
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of tamoxifen in laboratory animals.
Jordan VC; Allen KE; Dix CJ
Cancer Treat Rep; 1980; 64(6-7):745-59. PubMed ID: 6775807
[TBL] [Abstract][Full Text] [Related]
19. Additive and synergistic antitumor effects with toremifene and interferons.
Kangas L; Cantell K; Schellekens H
J Steroid Biochem; 1990 Jun; 36(3):259-62. PubMed ID: 2142249
[TBL] [Abstract][Full Text] [Related]
20. Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: an in situ hybridization study.
Shughrue PJ; Lane MV; Merchenthaler I
Endocrinology; 1997 Dec; 138(12):5476-84. PubMed ID: 9389534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
